Research
Hormonal
GLP-1 agonists (semaglutide, liraglutide, tirzepatide) produce significantly greater weight loss than placebo when combined with lifestyle modifications in adults and adolescents without type 2 diabetes.
If you have obesity and lifestyle changes haven't been enough, GLP-1 medications like semaglutide or tirzepatide are significantly more effective than placebo when combined with diet and exercise. Expect side effects like nausea, which are usually manageable, and commit to a treatment duration of at least 5-7 months to see full results.
GoodSupportsHIGH confidence
Using particular drug in addition to lifestyle modification appears to be more effective than using placebo with lifestyle modification.
Why this rating
Based on multiple randomized, double-blind, placebo-controlled trials cited in the review.
Source
GLP-1 agonists in treatment of obesity
Władysław ORŁOWSKI et al. · Journal of Education Health and Sport · 2023
DOI 10.12775/jehs.2023.13.02.033
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →